Company intelligence / Profile preview

Codigo

Hatfield or Philadelphia area, Pennsylvania, United Statescodigo1530.com ↗

Ownership: Private
Development stage: Other

Overview

Code Biotherapeutics is developing a proprietary non-viral gene therapy platform called 3DNA®, designed to overcome key limitations of current gene therapies such as dose-related toxicity, off-target effects, immunogenicity, and inability to re-dose. The company’s most advanced programs are in preclinical/IND-enabling stages targeting Duchenne muscular dystrophy and type 1 diabetes. No clinical results have been reported yet.

Therapeutic areas: Rare DiseasesEndocrinology
Modalities: Gene therapySynthetic DNA delivery platform (3DNA®)
Industry: Biotech

Partnerships

Amgen VenturesUCB VenturesTakeda Ventures

Beyond the preview

Go deeper on Codigo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Codigo.

Explore the full profile